Deep China Price Cuts Reveal Complex Considerations
This article was originally published in PharmAsia News
Offering deep price discounts in exchange for inclusion in reimbursement lists is never easy, given companies' need to balance expected benefits in volume gains with their international pricing systems and commercial pressures. But in China the underlying considerations are even more complex, as shown by the latest round of national price reductions for selected drugs.
You may also be interested in...
Cancer drug prices again on the chopping board in China, including for some products already affected, and more are coming.
Rapid regulatory changes in China are expected to trigger a flurry of new drug launch activities. As Q3 earnings season plays out, Gilead COO Kevin Young talks about doing ‘the right thing’ while rolling out products like the high-priced Sovaldi in China's private-pay market.
Off-patent original drugs in China are set to face unprecedented competition as the country drives up policy support for high-quality, bioequivalent domestic generics, and outlines other sweeping moves covering pricing and compulsory licenses.